A Phase 1 clinical trial showed that TARP peptide vaccination slows PSA doubling time and tumor growth rate in Stage D0 PCa patients with biochemical PSA recurrence (NCT00972309) [45]. The gene discussed is PROS1; the disease is neoplasm.